Ind-Swift Labs aims to touch Rs 1500cr turnover by 2015

Drug firm Ind-Swift Laboratories has set a target of achieving revenues of Rs 1,500 crore by 2015 with overseas markets like Japan, the European Union and the United States being the main growth drivers.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead Realasset
moneycontrol.com

Home » News » Business

Dec 09, 2012, 08.26 PM | Source: PTI

Ind-Swift Labs aims to touch Rs 1500cr turnover by 2015

Drug firm Ind-Swift Laboratories has set a target of achieving revenues of Rs 1,500 crore by 2015 with overseas markets like Japan, the European Union and the United States being the main growth drivers.

Like this story, share it with millions of investors on M3

Ind-Swift Labs aims to touch Rs 1500cr turnover by 2015

Drug firm Ind-Swift Laboratories has set a target of achieving revenues of Rs 1,500 crore by 2015 with overseas markets like Japan, the European Union and the United States being the main growth drivers.

Post Your Comments

Share Cancel

Drug firm Ind-Swift Laboratories has set a target of achieving revenues of Rs 1,500 crore by 2015 with overseas markets like Japan, the European Union and the United States being the main growth drivers.

"We expect to achieve revenues of Rs 1,500 crore by 2015. European Union, Japan, Australia and US will be the main drivers of growth for future," Ind-Swift Laboratories Vice Chairman cum Managing Director NR Munjal told PTI.

Ind-Swift Laboratories is currently witnessing 15 per cent to 20 per cent growth, he added.

"The current revenues of the company at present stand at over Rs 1,000 crore," Munjal said.

The main focus of the business for Ind-Swift laboratories continues to be its active pharmaceuticals Ingredients (API) business, he added.

Established in 1995, Ind-Swift's business model is focussed on domestic market and high-value mature regulated markets along with considerable focus on the emerging markets as well.

The accreditations of the company's facilities from the US Food and Drug Administration (USFDA) for five products and Pharmaceuticals and Medical Devices Agency (PMDA), Japan for two products have boosted the efforts to tap these highly regulated markets for products, the company said.

In July this year, the company forayed in the contract research and manufacturing services (CRAMS) segment and received the first order from a European pharmaceutical company.

"The order is for developing a non-infringing process for a anti-diabetes molecule that is going off patent in next three to four years," a spokesperson of the Chandigarh based firm had then said.

The Chandigarh based drug firm has manufacturing sites at six different locations across India.

Ind-Swift stock price

On May 27, 2016, Ind-Swift closed at Rs 4.59, up Rs 0.07, or 1.55 percent. The 52-week high of the share was Rs 8.40 and the 52-week low was Rs 4.05.


The latest book value of the company is Rs -11.99 per share. At current value, the price-to-book value of the company was -0.38.

Ads by Google

Buy, Hold, Sell ? Hear it first on M3
Ind-Swift Labs aims to touch Rs 1500cr turnover by 2015

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login